Id: | acc1734 |
Group: | 2sens |
Protein: | AKT |
Gene Symbol: | AKT1 |
Protein Id: | P31749 |
Protein Name: | AKT1_HUMAN |
PTM: | phosphorylation |
Site: | Tyr347 |
Site Sequence: | VMYEMMCGRLPFYNQDHEKLF |
Disease Category: | Cancer |
Disease: | Osteosarcoma |
Disease Subtype: | |
Disease Cellline: | |
Disease Info: | |
Drug: | quercetin(QUE) |
Drug Info: | "Quercetin (QUE) is a naturally occurring flavonoid with antioxidant, anti-inflammatory, and potential anticancer properties, commonly found in various fruits, vegetables, and grains, and used as a dietary supplement for its purported health benefits." |
Effect: | modulate |
Effect Info: | "100 μM quercetin decreased the phosphorylation levels of AKT and BAD and increased the phosphorylation of ERK1/2, leading to the death of osteosarcoma cells." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 35447220 |
Sentence Index: | 35447220_10-11 |
Sentence: | "In addition, the ERK1/2 phosphorylation increased leading to osteosarcoma cell death since pre-treatment with the MEK inhibitor PD98059 had reverted QUE effect. Altogether, these results indicate that low concentrations of QUE stimulate osteoblastogenesis but have no effect on the growth of tumor osteoblast cells, for which only high concentrations are efficient." |
Sequence & Structure:
MSDVAIVKEGWLHKRGEYIKTWRPRYFLLKNDGTFIGYKERPQDVDQREAPLNNFSVAQCQLMKTERPRPNTFIIRCLQWTTVIERTFHVETPEEREEWTTAIQTVADGLKKQEEEEMDFRSGSPSDNSGAEEMEVSLAKPKHRVTMNEFEYLKLLGKGTFGKVILVKEKATGRYYAMKILKKEVIVAKDEVAHTLTENRVLQNSRHPFLTALKYSFQTHDRLCFVMEYANGGELFFHLSRERVFSEDRARFYGAEIVSALDYLHSEKNVVYRDLKLENLMLDKDGHIKITDFGLCKEGIKDGATMKTFCGTPEYLAPEVLEDNDYGRAVDWWGLGVVMYEMMCGRLPFYNQDHEKLFELILMEEIRFPRTLGPEAKSLLSGLLKKDPKQRLGGGSEDAKEIMQHRFFAGIVWQHVYEKKLSPPFKPQVTSETDTRYFDEEFTAQMITITPPDQDDSMECVDSERRPHFPQFSYSASGTA
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
AKT1 | IPATASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Completed | metastatic prostate cancer | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Active, not recruiting | breast neoplasm | ClinicalTrials |
AKT1 | IPATASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Completed | triple-negative breast cancer | ClinicalTrials |
AKT1 | IPATASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Recruiting | cancer | ClinicalTrials |
AKT1 | IPATASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Active, not recruiting | breast cancer | ClinicalTrials |
AKT1 | IPATASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Completed | breast cancer | ClinicalTrials |
AKT1 | IPATASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Terminated | breast cancer | ClinicalTrials |
AKT1 | AFURESERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Recruiting | breast cancer | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Active, not recruiting | breast cancer | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Recruiting | breast cancer | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Recruiting | prostate cancer | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 3 | Active, not recruiting | prostate cancer | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | hepatocellular carcinoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | head and neck squamous cell carcinoma | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 2 | Active, not recruiting | neoplasm of mature B-cells | ClinicalTrials |
AKT1 | UPROSERTIB | Serine/threonine-protein kinase AKT inhibitor | 2 | Terminated | acute myeloid leukemia | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 2 | Active, not recruiting | adenocarcinoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | breast carcinoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Terminated | breast carcinoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | adenosquamous lung carcinoma | ClinicalTrials |
AKT1 | UPROSERTIB | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | breast carcinoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | bronchoalveolar adenocarcinoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Completed | diffuse large B-cell lymphoma | ClinicalTrials |
AKT1 | MK-2206 | Serine/threonine-protein kinase AKT inhibitor | 2 | Terminated | diffuse large B-cell lymphoma | ClinicalTrials |
AKT1 | CAPIVASERTIB | Serine/threonine-protein kinase AKT inhibitor | 2 | Terminated | gastric adenocarcinoma | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
AKT1-Ser124 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.707 | ||||
HGSC | 0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
AKT1-Ser126 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.707 | ||||
HGSC | 0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
AKT1-Ser129 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.707 | ||||
HGSC | 0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
AKT1-Thr448 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | -0.707 | ||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.707 |
AKT1-Thr450 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.936 | ||||
HGSC | -1.526 | ||||
ccRCC | 0.252 | ||||
GBM | 0.594 | ||||
HNSC | |||||
LUAD | 0.617 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.999 |
AKT1-Tyr315 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | 0.788 | ||||
COAD | |||||
HGSC | |||||
ccRCC | |||||
GBM | |||||
HNSC | |||||
LUAD | -1.125 | ||||
LUSC | 0.336 | ||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
AKT1S1-Ser183 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | 1.667 | ||||
COAD | 0.891 | ||||
HGSC | 0.725 | ||||
ccRCC | -1.189 | ||||
GBM | 0.792 | ||||
HNSC | 0.064 | ||||
LUAD | -0.194 | ||||
LUSC | -0.266 | ||||
non_ccRCC | -1.722 | ||||
PDAC | -0.879 | ||||
UCEC | 0.11 |
AKT1S1-Ser202 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -0.344 | ||||
COAD | -0.013 | ||||
HGSC | -2.725 | ||||
ccRCC | -0.093 | ||||
GBM | -0.249 | ||||
HNSC | 0.707 | ||||
LUAD | 0.324 | ||||
LUSC | 0.615 | ||||
non_ccRCC | 0.322 | ||||
PDAC | 0.379 | ||||
UCEC | 1.076 |
AKT1S1-Ser203 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -0.189 | ||||
COAD | 0.095 | ||||
HGSC | -2.902 | ||||
ccRCC | 0.277 | ||||
GBM | 0.142 | ||||
HNSC | 0.479 | ||||
LUAD | 0.265 | ||||
LUSC | 0.603 | ||||
non_ccRCC | 0.04 | ||||
PDAC | 0.419 | ||||
UCEC | 0.771 |
AKT1S1-Ser211 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.13 | ||||
COAD | 0.333 | ||||
HGSC | -2.178 | ||||
ccRCC | 0.627 | ||||
GBM | 0.09 | ||||
HNSC | 1.177 | ||||
LUAD | -0.47 | ||||
LUSC | 0.383 | ||||
non_ccRCC | |||||
PDAC | 0.715 | ||||
UCEC | 0.451 |
AKT1S1-Ser212 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.05 | ||||
COAD | 0.546 | ||||
HGSC | -2.08 | ||||
ccRCC | -0.197 | ||||
GBM | 0.641 | ||||
HNSC | 1.003 | ||||
LUAD | -0.628 | ||||
LUSC | 0.311 | ||||
non_ccRCC | |||||
PDAC | 0.36 | ||||
UCEC | 1.094 |
AKT1S1-Ser247 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -1.124 | ||||
HGSC | |||||
ccRCC | |||||
GBM | 0.791 | ||||
HNSC | 0.334 | ||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
AKT1S1-Ser88 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.265 | ||||
COAD | -0.583 | ||||
HGSC | |||||
ccRCC | -0.267 | ||||
GBM | 0.344 | ||||
HNSC | 2.36 | ||||
LUAD | -0.052 | ||||
LUSC | 0.649 | ||||
non_ccRCC | -0.088 | ||||
PDAC | -0.187 | ||||
UCEC | -0.912 |
AKT1S1-Ser92 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | -1.122 | ||||
COAD | -0.689 | ||||
HGSC | |||||
ccRCC | 0.068 | ||||
GBM | -0.037 | ||||
HNSC | 2.235 | ||||
LUAD | 0.28 | ||||
LUSC | 0.221 | ||||
non_ccRCC | -0.997 | ||||
PDAC | 0.777 | ||||
UCEC | -0.735 |
AKT1S1-Thr198 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | |||||
HGSC | |||||
ccRCC | -0.647 | ||||
GBM | |||||
HNSC | |||||
LUAD | -0.505 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 1.152 |
AKT1S1-Thr246 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | -0.468 | ||||
HGSC | 0.953 | ||||
ccRCC | |||||
GBM | -1.179 | ||||
HNSC | |||||
LUAD | |||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC | 0.694 |
AKT1S1-Thr90 | |||||
---|---|---|---|---|---|
Cancer | Intensity | ||||
BRCA | |||||
COAD | 0.347 | ||||
HGSC | -1.784 | ||||
ccRCC | 0.431 | ||||
GBM | |||||
HNSC | 0.542 | ||||
LUAD | 0.465 | ||||
LUSC | |||||
non_ccRCC | |||||
PDAC | |||||
UCEC |
AKT1S1-Thr97 | |
---|---|
Cancer | Intensity |
BRCA | 1.061 |
COAD | -1.872 |
HGSC | |
ccRCC | 0.814 |
GBM | -0.592 |
HNSC | 0.541 |
LUAD | 0.201 |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC | -0.152 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
- | - | D | Sepsis | Acetylation | 37211747 |
S | 124 | D | Pancreatic ductal adenocarcinoma | Phosphorylation | 27014871 |
S | 473 | D | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
T | 308 | D | Diabetes mellitus | Phosphorylation | 17272402 ;  20938636 ;  15919790 |
T | 308 | D | Ovarian cancer/carcinoma | Phosphorylation | 20153512 |
T | 308 | D | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 |
T | 308 | D | Type 2 diabetes | Phosphorylation | 15919790 ;  15919790 |
S | 473 | D | Triple-negative breast cancer | Phosphorylation | 34077419 |
S | 473 | D | Bladder cancer | Phosphorylation | 23799035 |
S | 473 | D | Pancreatic cancer | Phosphorylation | 28363942 ;  15467756 |
- | - | D | Oral squamous cell carcinoma | Phosphorylation | 23723304 |
- | - | D | Laryngeal cancer | Phosphorylation | 23886414 |
- | - | D | Myelodysplasia | Phosphorylation | 12529294 |
- | - | D | Glioma/adult gliomas | Phosphorylation | 12839945 |
S | 473 | D | Colon cancer | Phosphorylation | 35190555 |
S | 473 | D | Oral squamous cell carcinoma | Phosphorylation | 31889370 |
T | 554 | N | Ovarian clear cell carcinoma | Phosphorylation | 24299208 |
K | 64 | P | Non-small cell lung cancer | Methylation | 30692626 |
S | 129 | P | Lung cancer/carcinoma | Phosphorylation | 24008396 |
S | 473 | P | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 18056483 |
S | 473 | P | Gastric cancer | Phosphorylation | 23969493 ;  23440515 |
S | 473 | P | Ovarian cancer/carcinoma | Phosphorylation | 23877012 |
T | 308 | P | Non-small cell lung cancer/carcinoma | Phosphorylation | 23091605 |
- | - | P | Brain cancer | Phosphorylation | 12388552 |
- | - | P | Embryonal central nervous system tumor | Phosphorylation | 16230398 |
- | - | P | Glioblastoma | Phosphorylation | 23262078 |
- | - | P | Acute monocytic leukemia | Phosphorylation | 24422998 |
S | - | P | Colon cancer/carcinoma | Phosphorylation | 24464560 |
S | 473 | P | Anaplastic astrocytoma | Phosphorylation | 23596468 |
S | 473 | P | Esophageal squamous cell carcinoma | Phosphorylation | 23510069 |
S | 473 | P | Non-small cell lung cancer/carcinoma | Phosphorylation | 23091605 |
S | 473 | P | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 23732709 |
S | 473 | P | Breast cancer | Phosphorylation | 36632451 |
- | - | P | Cancer | SUMOylation | 23884910 |
- | - | U | Hepatocellular carcinoma | Acetylation | 31842909 |
- | - | U | Papillary thyroid cancer | Acetylation | 37696385 |
K | 426 | U | Breast cancer | Acetylation | 32499521 |
S | 473 | U | Urethral cancer | Phosphorylation | 22975685 |
S | 473 | U | Thymic carcinoma | Phosphorylation | 20597130 |
S | 473 | U | Systemic lupus erythematosus | Phosphorylation | 23735868 ;  34522717 ;  23735868 |
S | 473 | U | Squamous cell carcinoma | Phosphorylation | 21795477 ;  37109043 |
S | 473 | U | Sjogren's syndrome | Phosphorylation | 34948236 |
S | 473 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 17545609 ;  12244301 ;  22476852 |
S | 473 | U | Cancer | Phosphorylation | 21795477 |
S | 473 | U | Cholangiocarcinoma | Phosphorylation | 37752233 |
S | 473 | U | Colon cancer/carcinoma | Phosphorylation | 22975685 |
S | 473 | U | Colorectal cancer | Phosphorylation | 37430297 |
S | 473 | U | Diabetes mellitus | Phosphorylation | 35835217 |
S | 473 | U | Glioma | Phosphorylation | 33820494 |
S | 473 | U | HER2-positive breast cancer | Phosphorylation | 36314765 |
S | 473 | U | Kidney cancer | Phosphorylation | 12649200 ;  12649200 ;  22580611 |
S | 473 | U | Liver cancer | Phosphorylation | 15684384 |
S | 473 | U | Lymphocytic leukemia | Phosphorylation | 20576813 |
S | 473 | U | Melanoma | Phosphorylation | 19996208 ;  12499277 ;  12499277 ;  19996208 ;  12499277 |
S | 473 | U | Neuroblastoma | Phosphorylation | 17234785 |
S | 473 | U | Non-small cell squamous cell lung carcinoma | Phosphorylation | 20008839 |
S | 473 | U | Obesity | Phosphorylation | 35413055 |
S | 473 | U | Ovarian cancer | Phosphorylation | 15208673 |
S | 473 | U | Ovarian epithelial carcinoma | Phosphorylation | 32194423 |
S | 473 | U | Pancreatic cancer | Phosphorylation | 15467756 ;  28363942 |
S | 473 | U | Parkinson's disease | Phosphorylation | 19800394 ;  19800394 ;  21658387 |
S | 473 | U | Renal cancer/carcinoma | Phosphorylation | 19118035 ;  16247451 ;  12649200 |
T | 308 | U | Breast cancer | Phosphorylation | 33571243 |
T | 308 | U | Chronic lymphocytic leukemia | Phosphorylation | 16940331 |
T | 308 | U | Melanoma | Phosphorylation | 19996208 |
T | 308 | U | Multiple myeloma | Phosphorylation | 37781194 |
T | 308 | U | Neuroblastoma | Phosphorylation | 17234785 |
T | 308 | U | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 26676747 |
T | 308 | U | Rhabdomyosarcoma | Phosphorylation | 17848913 |
T | 450 | U | Cholangiocarcinoma | Phosphorylation | 35625759 |
T | 308 | U | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 12750723 |
T | 308 | U | Cholangiocarcinoma | Phosphorylation | 37752233 |
T | 308 | U | Lymphocytic leukemia | Phosphorylation | 20576813 |
T | 308 | U | Obesity | Phosphorylation | 35413055 |
T | 308 | U | Sjogren's syndrome | Phosphorylation | 34948236 |
T | 308 | U | Endometrial cancer | Phosphorylation | 35253622 |
T | 308 | U | Esophageal squamous cell carcinoma | Phosphorylation | 36995521 |
Y | 176 | U | Breast cancer/tumor/carcinoma | Phosphorylation | 20333297 |
Y | 176 | U | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 22322295 |
- | - | U | Tongue cancer | Phosphorylation | 37132640 |
- | - | U | Epithelial ovarian cancer | Phosphorylation | 35105347 |
- | - | U | Urothelial bladder cancer | Phosphorylation | 35691981 |
- | - | U | Gastric cancer | Phosphorylation | 36604355 |
- | - | U | Colorectal cancer | Phosphorylation | 35110545 |
- | - | U | Pancreatic cancer | Phosphorylation | 31765735 |
- | - | U | Marek's disease | Phosphorylation | 35795905 |
- | - | U | Renal cell carcinoma | Phosphorylation | 34257606 |
S | 473 | U | Cancer | Phosphorylation | 34767444 |
- | - | U | Gastric cancer | Phosphorylation | 23898095 |
- | - | U | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 23785446 |
- | - | U | Prostate cancer/carcinoma/adenocarcinoma | Phosphorylation | 10853013 |
- | - | U | Cervical cancer/carcinoma | Phosphorylation | 10853013 |
- | - | U | Thyroid cancer | Phosphorylation | 12788904 |
- | - | U | Endometrial cancer | Phosphorylation | 12888921 |
S | 473 | U | Acute myeloid leukemia/acute myelogenous leukemia | Phosphorylation | 15289327 |
S | 473 | U | Breast cancer | Phosphorylation | 17545609 ;  12244301 ;  12244301 ;  17545609 ;  21743495 ;  30413706 |
S | 473 | U | Chronic lymphocytic leukemia | Phosphorylation | 16940331 |
S | 473 | U | Esophageal squamous cell carcinoma | Phosphorylation | 31897228 |
S | 473 | U | Gallbladder cancer | Phosphorylation | 33407730 |
S | 473 | U | Hepatocellular carcinoma | Phosphorylation | 37573318 ;  36348350 |
S | 473 | U | Multiple myeloma | Phosphorylation | 37781194 |
S | 473 | U | Pancreatic cancer/carcinoma/adenocarcinoma | Phosphorylation | 15467756 ;  21474066 ;  28363942 |
S | 473 | U | Rhabdomyosarcoma | Phosphorylation | 17848913 |
S | 473 | U | Synovial sarcoma | Phosphorylation | 35556229 |
S | 473 | U | Cervical cancer | Phosphorylation | 32047568 |
S | 473 | U | Osteosarcoma | Phosphorylation | 34476004 |
S | 473 | U | Uveal melanoma | Phosphorylation | 34918581 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.